Omnicell, Inc. (OMCL) News
Follow Omnicell, Inc. (OMCL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
OMCL: Transformation centers on Titan XT and OmniSphere, with disciplined growth and innovation focus
Management is driving a multi-year transformation with the Titan XT and OmniSphere platforms, focusing on innovation, customer experience, and flexible upgrade paths. Financial discipline is prioritized, with targeted in
EQUITY | Sep 09, 2026, 06:22 PM UTC
L
OMCL: Titan XT and OmniSphere drive innovation, margin focus, and market share gains in a robust refresh cycle
Management is driving a multi-year transformation with the Titan XT and OmniSphere platforms, focusing on innovation, customer experience, and flexible financing to capture market share. Margin expansion and disciplined
EQUITY | Sep 09, 2026, 05:51 PM UTC
L
TraceLink and Omnicell integrate DSCSA compliance into hospital pharmacies
TraceLink and Omnicell say their DSCSA compliance solution will bring serialized product verification and traceability into medication receiving workflows, aimed at enabling more efficient hospital pharmacy operations wi
EQUITY | Sep 03, 2026, 02:01 PM UTC
L
OMCL - TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
OMCL - TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
EQUITY | Sep 03, 2026, 02:00 PM UTC
L
Omnicell to present at Wells Fargo 21st Healthcare Conference
Omnicell will present at the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Aug 31, 2026, 08:01 PM UTC
L
OMCL Reiterate Overweight after two day NDR meetings @ KEYB
OMCL Reiterate Overweight after two day NDR meetings @ KEYB
EQUITY | Aug 24, 2026, 11:51 AM UTC
L
OMCL Q2 saw solid results, but reduced the low end of its FY26 product bookings guide @ KEYB
OMCL Q2 saw solid results, but reduced the low end of its FY26 product bookings guide @ KEYB
EQUITY | Jul 31, 2026, 11:01 AM UTC
L
Omnicell Raises FY2026 Adj EPS Guidance from $1.80-$2.00 to $2.15-$2.30 vs $1.94 Est; Narrows FY2026 Sales Guidance from $1.215B-$1.255B to
Omnicell (NASDAQ: OMCL ) raises FY2026 Adj EPS guidance from $1.80-$2.00 to $2.15-$2.30 vs $1.94 analyst estimate. Narrows FY2026 sales outlook from $1.215 billion-$1.255 billion to $1.225 billion-$1.245 billion vs $1.24
EARNINGS | Jul 30, 2026, 10:40 AM UTC
L
OMCL Omnicell RESULTS: Q2, Q2 REV $312M, Q2 ADJ EBITDA $67M, Q2 Net Income $24M, Q2 ADJ Net Income $44M, Omnicell Earnings Notes:, Outlook Q
OMCL Omnicell RESULTS: Q2, Q2 REV $312M, Q2 ADJ EBITDA $67M, Q2 Net Income $24M, Q2 ADJ Net Income $44M, Omnicell Earnings Notes:, Outlook Q3 ADJ EPS $0.35-0.43, Guides Q3 2026 REV $301M-$307M
EARNINGS | Jul 30, 2026, 10:32 AM UTC
L
Omnicell Appoints COO Nnamdi Njoku As President, Effective July 1
Omnicell, Inc. (NASDAQ: OMCL ) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Nnamdi Njoku has been appointed Presiden
GEOPOLITICS | Jul 01, 2026, 12:16 PM UTC